
The TRACK-TBI cohort study assessed early beta-blocker exposure in moderate-severe TBI patients and its association with neuronal injury biomarkers. No significant effects were observed at day 3; however, a sustained reduction in NSE levels by day 14 suggests possible neuroprotective effects. While findings are exploratory, they support further trials to validate beta-blockers as a therapeutic adjunct in TBI management.
Like
Save
Share